The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). OS was significantly...
HD Hyundai Vice Chairman Chung Kisun Promoted to Chairman
SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- HD Hyundai announced that Executive Vice Chairman Chung Kisun has been promoted to Chairman in its latest executive appointments. Chung Kisun, HD Hyundai Chairman Chairman Chung holds a bachelor's...
From Corporate Social Responsibility To Global Consensus: Chery's "Ride Green Life" Unites the World for a Sustainable Future
WUHU, China, Oct. 20, 2025 /PRNewswire/ -- As the global automotive industry accelerates toward a green, low-carbon future, corporate social responsibility has evolved — now defined by sustainable practices fostering harmony between people, society,...
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions
LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic move enhances...
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, Results from a Phase 3 study of...
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate...
Zeekr Group to Report Third Quarter 2025 Financial Results on November 17, 2025
HANGZHOU, China, Oct. 20, 2025 /PRNewswire/ -- ZEEKR Intelligent Technology Holding Limited ("Zeekr Group" or the "Company") (NYSE: ZK), the world's leading premium new energy vehicle group, today announced that it will report its unaudited...
KLN Drives Libya's Wellhead Platform A Project Toward Completion, One of the Mediterranean Sea's Largest Offshore EPCI Projects to Bolster Energy Infrastructure
HONG KONG, Oct. 20, 2025 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK), through its division KLN Project, today announced significant progress on the Wellhead Platform A (WHPA) project in Libya's Bahr Essalam field. As...
Chery Group Renews US$6 Million Partnership with UNICEF to Advance Global Education
WUHU, China, Oct. 20, 2025 /PRNewswire/ -- Chery Group and UNICEF today announced the renewal of their global partnership in education, launching a new three-year collaboration to transform the lives of children worldwide, especially the most...
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3...